Please assess the completion status of the following clinical trial:

Trial Title: Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed brain tumors, including any of the following:~  * Brain stem glioma~ * Primitive neuroectodermal tumor~ * CNS germ cell tumor~ * Malignant glioma~* Diagnosis based on any of the following:~  * CT-assisted or stereotactic biopsy~ * Open biopsy~ * Surgical resection~ * Cerebrospinal fluid cytology~ * Elevated tumor markers~ * Unequivocal radiographic changes (for patients with brain stem glioma or optic glioma)~* All tumor types, except brain stem glioma, must be recurrent~* No radiographic signs of intracranial herniation and/or spinal cord block~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* At least 90 days~Hematopoietic~* WBC ≥ 2,500/mm\^3~* Absolute granulocyte count ≥ 1,200/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* SGOT and SGPT \< 2.5 times upper limit of normal~* Bilirubin \< 2.0 mg/dL~Renal~* Creatinine \< 1.8 mg/dL~Pulmonary~* No history of clinically significant reactive airway disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No significant risk for general anesthesia~* No uncontrolled, clinically significant, confounding medical condition within the past 30 days~* No contraindication to study drugs~PRIOR CONCURRENT THERAPY:~Chemotherapy~* At least 28 days since prior systemic chemotherapy~Radiotherapy~* At least 3 months since prior total spine radiotherapy~* At least 14 days since prior cranial radiotherapy~* Prior systemic radiotherapy allowed~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).